Last reviewed · How we verify
MydCombi Drug
MydCombi Drug is a combination of mycophenolate mofetil and cyclosporine, which works by suppressing the immune system to prevent organ rejection.
MydCombi Drug is a combination of mycophenolate mofetil and cyclosporine, which works by suppressing the immune system to prevent organ rejection. Used for Prevention of organ rejection in kidney transplant patients.
At a glance
| Generic name | MydCombi Drug |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | immunosuppressant |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase, an enzyme crucial for lymphocyte proliferation, while cyclosporine inhibits calcineurin, a key component of the T-cell activation pathway. This dual mechanism of action results in a synergistic immunosuppressive effect, reducing the risk of organ rejection in transplant patients.
Approved indications
- Prevention of organ rejection in kidney transplant patients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Leukopenia
- Thrombocytopenia
- Anemia
- Hypertension
- Hyperkalemia
- Hyperuricemia
Key clinical trials
- Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients (PHASE4)
- Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |